Immune monitoring of surgical colorectal malignancies through carcinoembryonic antigen and alpha-fetoprotein serum levels, flow-cytometric blood lymphocyte phenotyping and tumor DNA analysis.
67 patients with operable colorectal adenocarcinomas were divided into two groups based on criteria referring to DNA flow-cytometric models and the histopathological type and stage of intraoperatively harvested tumor samples: low-aggressive tumor group and highly aggressive tumor group. Two kinds of immunological markers were investigated: humoral (carcinoembryonic antigen and alpha-fetoprotein serum levels were measured by ELISA) and cellular (blood lymphocyte counts of the following subpopulations: CD3+, CD4+, CD8+/CD11b+, CD19+, CD16+/CD56+, HLA-DR+/CD3+, measured by means of flow cytometry). All assays were similarly performed before and 2, 4, 6 and 8 weeks after tumor exeresis. Results seem to reveal a relationship between patients without immunological recovering and a bad postoperative clinical evolution of the highly aggressive colorectal malignant tumors. The significance of multiway immune monitoring of colorectal cancer is discussed.
Voiculescu
C
C
Department of Immunology, Faculty of Medicine, Craiova, Romania.
Avramescu
C
C
Radu
E
E
Valcea
V
V
D000328:Adult; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen / Q000097:blood; D016022:Case-Control Studies; D015179:Colorectal Neoplasms / Q000097:blood / Q000276:immunology* / Q000601:surgery*; D004273:DNA, Neoplasm / Q000032:analysis; D005434:Flow Cytometry; D006801:Humans; D016131:Lymphocyte Subsets / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015166:Monitoring, Immunologic / Q000379:methods*; D010641:Phenotype; D011379:Prognosis; D000509:alpha-Fetoproteins / Q000378:metabolism
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D004273:DNA, Neoplasm; D000509:alpha-Fetoproteins